UniQure rises on plans to cut about 20% of workforce
** U.S-listed shares of Dutch gene therapy maker uniQure
UQ1.F QURE.O rise ~8.3% to $6.53
** Co says it will cut about 20% of its total workforce and
end investments in more than half of its research and technology
projects to reduce costs
** Says it expects to generate savings of about $180 mln
over the next three years with the restructuring
** Including session moves, shares down ~70.3% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Recent news on uniQure
See all newsuniQure tumbles after updated Huntington's disease gene therapy data
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal